



Material suplementario

Repercusiones en la posología de los anticoagulantes orales no antagonistas de la vitamina K por las variaciones de la función renal de los pacientes con fibrilación auricular e insuficiencia cardiaca aguda reciente

^aServicio de Cardiología, Hospital Clínico Universitario Virgen de la Arrixaca, El Palmar, Murcia, España

^bLaboratorio de Análisis Clínicos, Hospital Clínico Universitario Virgen de la Arrixaca, El Palmar, Murcia, España

^cServicio de Cardiología, Hospital Universitario Los Arcos del Mar Menor, San Javier, Murcia, España

^dCentre for Cardiovascular Sciences, City Hospital, University of Birmingham, Birmingham, Reino Unido

^eServicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Murcia, España

Table 1 of the supplementary material

Renal Function Variation According to Hypothetical Need for Dosage Adjustment of Each Nonvitamin K Oral Anticoagulants

	Hypothetical need for dosage adjustment								
	Dabigatran			Rivaroxaban			Apixaban		
	No (n = 90)	Yes (n = 72)	<i>P</i>	No (n = 105)	Yes (n = 57)	<i>P</i>	No (n = 115)	Yes (n = 47)	<i>P</i>
CrCl relative variation, %	23 (14)	55 (55)	<.001	25 (17)	58 (61)	<.001	27 (18)	62 (65)	<.001
CrCl absolute variation, L/min	16 (14)	24 (21)	.004	16 (13)	27 (23)	<.001	18 (14)	24 (25)	.073

Data are expressed as mean ± standard deviation

Table 2 of the supplementary material

Percentage of Patients That Would Have Needed at Least 1 Hypothetical Dosage Adjustment of Each Nonvitamin K Oral Anticoagulant According to Creatinine Clearance at Hospital Discharge

	Creatinine clearance at discharge							
	<15 mL/min (n = 1)	15-24.9 mL/min (n = 9)	25-34.9 mL/min (n = 20)	35-44.9 mL/min (n = 26)	45-54.9 mL/min (n = 22)	55-64.9 mL/min (n = 26)	65-74.9 mL/min (n = 19)	≥75 mL/min (n = 39)
Dabigatran	1 (100%)	2 (22%)	14 (70%)	16 (62%)	16 (73%)	12 (46%)	8 (42%)	3 (8%)
Rivaroxaban	1 (100%)	4 (44%)	3 (15%)	11 (42%)	15 (69%)	12 (46%)	8 (42%)	3 (8%)
Apixaban	1 (100%)	5 (56%)	15 (75%)	13 (50%)	6 (27%)	4 (15%)	2 (11%)	1 (3%)

Figure 1 of the supplementary material. Flow diagram for participants included in the study.

